TL;DR: The Centers for Medicare & Medicaid Services modified NCD 53, its HIV testing (diagnosis) coverage policy, with an effective date of January 9, 2026. Here's what billing teams need to know.
This update to NCD 53 in the Medicare system clarifies the diagnostic criteria that support HIV testing coverage. The policy does not list specific CPT or HCPCS codes — which means HIV testing billing depends on accurate ICD-10 diagnosis coding and well-documented medical necessity. Get your documentation workflows aligned before January 9, 2026.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | CMS (Centers for Medicare & Medicaid Services) |
| Policy | Human Immunodeficiency Virus (HIV) Testing (Diagnosis) |
| Policy Code | NCD 53 |
| Change Type | Modified |
| Effective Date | January 9, 2026 |
| Impact Level | Medium |
| Specialties Affected | Infectious disease, internal medicine, primary care, obstetrics, emergency medicine, oncology, neurology |
| Key Action | Audit clinical documentation templates to confirm all 11 covered indications are capturable before January 9, 2026 |
CMS HIV Testing Coverage Criteria and Medical Necessity Requirements 2026
NCD 53 is the National Coverage Determination governing Medicare coverage of HIV diagnostic testing. The Centers for Medicare & Medicaid Services uses this policy to define when HIV testing is medically necessary for diagnosis — not screening, but confirmatory workup driven by clinical suspicion.
That distinction matters for HIV testing billing. Screening tests follow a separate coverage path under preventive services. NCD 53 covers diagnostic testing — meaning the clinician already has a clinical reason to suspect HIV infection and is ordering tests to confirm or rule it out.
The coverage policy requires a "strong clinical suspicion" supported by one or more of 11 documented clinical findings. All 11 are covered, but every one of them requires documented evidence in the medical record. Weak or missing documentation is a direct path to claim denial.
What "Strong Clinical Suspicion" Actually Means for Your Claims
CMS does not define a threshold for what counts as "strong." That ambiguity is real, and it creates risk. Your clinicians need to do more than check a box — they need to document the specific finding that triggered the test order.
A claim for HIV diagnostic testing with only a vague note of "rule out HIV" is exposed. The record needs to show the specific indication: an AIDS-defining opportunistic infection, an unexplained immune deficiency presentation, a documented sexually transmitted disease, acute retroviral syndrome, or one of the other listed criteria.
The policy also addresses diagnostic methods directly. Serologic assays are the primary tool — either antibody detection assays (typically enzyme immunoassays, or EIA) or the HIV-1 core antigen (p24) test. When an initial EIA is repeatedly positive or indeterminate, confirmatory testing with Western Blot is expected. Your documentation should reflect this diagnostic sequence, not just the final test ordered.
When Serology Alone Isn't Enough
NCD 53 identifies three situations where serologic testing alone may not reliably establish HIV infection. CMS explicitly requires laboratory evidence of HIV through culture, antigen assays, proviral DNA, or viral RNA assays in these cases.
The three situations are: acute retroviral syndrome (where IgG antibody response hasn't developed yet), persistent equivocal results from inherent viral antigen variability, and perinatal HIV infection (where maternal antibody passes transplacentally and confounds the result).
If your practice handles perinatal cases or sees patients presenting in early acute infection, your billing team needs to understand that standard serologic test claims may require supplemental documentation showing why more advanced assays were necessary. Missing that justification will trigger denial.
CMS HIV Testing Exclusions and Non-Covered Indications
NCD 53 does not cover HIV diagnostic testing on the basis of clinical suspicion alone — without supporting documented findings. Ordering a diagnostic HIV test because a patient "may be at risk" without any of the 11 enumerated clinical findings documented does not meet medical necessity under this coverage policy.
The p24 antigen test has a narrowed role under this policy. CMS notes its prognostic utility has diminished with the development of sensitive viral RNA assays. Its primary accepted use is as a routine screening tool for potential blood donors. Using p24 as a standalone diagnostic tool outside that context may face scrutiny.
HIV testing ordered outside of a documented clinical indication — for example, as part of a general wellness workup without any of the 11 listed findings — falls outside the scope of NCD 53 and should be billed as a preventive service if eligible, or with an ABN if the claim is likely to deny under Medicare.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| AIDS-defining or AIDS-associated opportunistic infection, otherwise unexplained | Covered | No specific CPT/HCPCS listed in NCD 53 | Requires documented, otherwise unexplained infection |
| Documented sexually transmitted disease with significant HIV exposure risk | Covered | No specific CPT/HCPCS listed in NCD 53 | Must document STD and risk of early or subclinical HIV infection |
| Documented acute or chronic hepatitis B or C with significant HIV exposure risk | Covered | No specific CPT/HCPCS listed in NCD 53 | HBV or HCV documentation required alongside HIV exposure risk |
| AIDS-defining or AIDS-associated neoplasm | Covered | No specific CPT/HCPCS listed in NCD 53 | Neoplasm must be documented |
| AIDS-associated neurologic disorder or unexplained dementia | Covered | No specific CPT/HCPCS listed in NCD 53 | Must be otherwise unexplained |
| AIDS-defining clinical condition or history of severe/recurrent/persistent conditions suggesting immune deficiency | Covered | No specific CPT/HCPCS listed in NCD 53 | Examples: cutaneous or mucosal disorders |
| Unexplained generalized signs/symptoms suggesting chronic process with immune deficiency | Covered | No specific CPT/HCPCS listed in NCD 53 | Examples: fever, weight loss, lymphadenopathy, chronic diarrhea, hemoptysis |
| Unexplained lab evidence of chronic disease with immune deficiency | Covered | No specific CPT/HCPCS listed in NCD 53 | Examples: anemia, leukopenia, pancytopenia, lymphopenia, low CD4+ count |
| Acute retroviral syndrome (fever, malaise, lymphadenopathy, skin rash) | Covered | No specific CPT/HCPCS listed in NCD 53 | May require RNA/DNA assays rather than serology alone |
| Documented exposure to blood/body fluids capable of transmitting HIV with antiviral therapy initiated or anticipated | Covered | No specific CPT/HCPCS listed in NCD 53 | Needle sticks and significant blood exposures qualify |
| Patient undergoing treatment for rape | Covered | No specific CPT/HCPCS listed in NCD 53 | Policy text is truncated — confirm full criteria with your compliance officer |
| Perinatal HIV infection | Covered (with non-serologic confirmation required) | No specific CPT/HCPCS listed in NCD 53 | Maternal antibody passage requires culture, antigen, proviral DNA, or viral RNA assay |
| HIV-1 antigen (p24) for general diagnosis | Limited | No specific CPT/HCPCS listed in NCD 53 | Primary accepted use is blood donor screening; standalone diagnostic use is exposed |
| Testing based on clinical suspicion without documented supporting findings | Not Covered | — | No enumerated indication = no coverage under NCD 53 |
CMS HIV Testing Billing Guidelines and Action Items 2026
NCD 53 doesn't list specific CPT or HCPCS codes. That's not unusual for an NCD covering lab diagnostics — codes are often mapped at the Medicare Administrative Contractor level or through local coverage determinations. But it means your billing team carries the full weight of getting the ICD-10 diagnosis coding and supporting documentation right.
Here's what to do before January 9, 2026:
| # | Action Item |
|---|---|
| 1 | Audit your EHR documentation templates for HIV diagnostic workups. Confirm that every applicable indication from the 11-item list can be captured as discrete, documented findings. If your templates only have a free-text "reason for test" field, that's a gap. Structured documentation fields tied to covered indications protect you at audit. |
| 2 | Separate your HIV screening workflows from your HIV diagnostic workflows. Screening and diagnosis are billed differently and covered under different policies. If your practice uses the same order set for both, fix that before the effective date of January 9, 2026. Misclassifying a diagnostic test as preventive — or vice versa — creates reimbursement problems in both directions. |
| 3 | Train your clinical staff on the p24 antigen test's limited diagnostic role. Under NCD 53, p24's primary use is blood donor screening. If physicians are ordering it as a standalone diagnostic tool, those claims are exposed. This is especially true now that viral RNA assays are the preferred alternative for cases where standard serology is unreliable. |
| 4 | Build a process for perinatal and acute retroviral syndrome cases. These two situations require non-serologic confirmation. When your billing team sees a claim for viral culture, proviral DNA, or viral RNA assay in the context of HIV diagnosis, there should be documentation in the record explaining why serology alone was insufficient. Without that explanation, the more expensive assay looks like an outlier and draws scrutiny. |
| 5 | Check with your Medicare Administrative Contractor for code-level guidance. NCD 53 doesn't enumerate CPT or HCPCS codes. Your local MAC may have a companion local coverage determination or billing guidelines that map specific lab codes to this NCD. Pull those documents now. If you're billing HIV diagnostic tests to Medicare without knowing your MAC's position on applicable codes, you're flying without instruments. |
| 6 | Issue ABNs appropriately when clinical documentation is borderline. If a physician wants to order HIV diagnostic testing but the documentation doesn't clearly support one of the 11 indications, get an Advance Beneficiary Notice of Noncoverage in place before the test is performed. Retroactive ABNs don't protect you from claim denial or recoupment. |
| 7 | Flag the rape treatment indication for compliance review. The NCD 53 policy summary was truncated at this indication. The full coverage criteria for patients undergoing treatment for rape are not visible in the available policy text. Talk to your compliance officer about this before January 9, 2026 — especially if your facility handles sexual assault cases. |
If your practice handles a high volume of infectious disease, oncology, or OB cases, loop in your compliance officer to review how NCD 53 intersects with your specific payer mix and documentation practices.
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for HIV Testing (Diagnosis) Under NCD 53
Covered CPT/HCPCS Codes
NCD 53 does not list specific CPT or HCPCS codes. The policy establishes coverage criteria and medical necessity standards for HIV diagnostic testing but does not enumerate procedure codes. Contact your Medicare Administrative Contractor for code-level billing guidelines applicable in your region.
Key ICD-10-CM Diagnosis Codes
NCD 53 does not list specific ICD-10-CM codes. However, your diagnosis codes must directly reflect one or more of the 11 documented clinical indications required for coverage. Examples of diagnosis categories that map to the covered indications include:
- AIDS-defining opportunistic infections (your coder should apply the specific organism/condition code)
- Documented sexually transmitted infections with HIV exposure risk
- Hepatitis B or C with concurrent HIV exposure documentation
- AIDS-defining neoplasms
- Unexplained neurologic conditions or dementia
- Immune deficiency signs and symptoms (fever, lymphadenopathy, weight loss, CD4 abnormalities)
- Occupational or significant blood/body fluid exposure
- Acute retroviral syndrome presentation
Work with your coding team to confirm that the ICD-10-CM codes you're assigning directly support the covered indication documented by the treating clinician. A mismatch between the physician's documented finding and the code on the claim is a common and preventable source of denial.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.